Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$4.60 +2.1%	$3.88	$3.21 ▼ $7.18	$1.10B	0.6	4.43 million shs	1.18 million shs
AUPH Aurinia Pharmaceuticals	$9.10 +1.2%	$8.10	$5.20 ▼ $10.67	$1.23B	1.16	1.40 million shs	591,309 shs
ELVN Enliven Therapeutics	$22.00 +1.6%	$19.86	$13.30 ▼ $30.03	$1.06B	0.83	301,736 shs	45,198 shs
INZY Inozyme Pharma	$4.00	$3.60	$0.72 ▼ $6.24	$258.25M	2.27	942,366 shs	N/A

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-2.39%	+0.45%	+25.00%	-2.17%	-24.37%
AUPH Aurinia Pharmaceuticals	-0.55%	+18.45%	+9.90%	+17.21%	+58.55%
ELVN Enliven Therapeutics	-5.87%	+8.63%	-1.19%	+34.72%	-13.75%
INZY Inozyme Pharma	0.00%	0.00%	+0.25%	+315.89%	-26.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.0638 of 5 stars	3.5	1.0	4.4	2.6	2.5	0.6
AUPH Aurinia Pharmaceuticals	3.155 of 5 stars	3.5	2.0	0.0	3.4	0.8	1.9
ELVN Enliven Therapeutics	2.7935 of 5 stars	3.5	2.0	0.0	2.5	4.2	0.0
INZY Inozyme Pharma	3.4856 of 5 stars	4.2	4.0	0.0	2.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	3.00	Buy	$10.89	136.97% Upside
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	26.44% Upside
ELVN Enliven Therapeutics	3.00	Buy	$41.20	87.32% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	193.75% Upside

Current Analyst Ratings Breakdown

Latest INZY, AUPH, ARDX, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/18/2025	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$333.61M	3.30	N/A	N/A	$0.73 per share	6.29
AUPH Aurinia Pharmaceuticals	$235.13M	5.23	$0.31 per share	29.31	$2.68 per share	3.39
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.22	N/A	14.82	N/A	-14.86%	-34.45%	-13.81%	7/30/2025 (Estimated)
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	32.41	16.24	N/A	16.11%	14.27%	9.93%	7/30/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	8/5/2025 (Estimated)

Latest INZY, AUPH, ARDX, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ELVN Enliven Therapeutics	-$0.54	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ARDX Ardelyx	-$0.12	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	AUPH Aurinia Pharmaceuticals	$0.18	N/A	N/A	N/A	$64.27 million	N/A
8/5/2025	Q2 2025	INZY Inozyme Pharma	-$0.36	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.04	4.12	3.81
AUPH Aurinia Pharmaceuticals	0.16	5.93	5.26
ELVN Enliven Therapeutics	N/A	21.07	21.06
INZY Inozyme Pharma	0.65	2.19	2.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
AUPH Aurinia Pharmaceuticals	36.83%
ELVN Enliven Therapeutics	95.08%
INZY Inozyme Pharma	88.30%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
AUPH Aurinia Pharmaceuticals	12.20%
ELVN Enliven Therapeutics	25.90%
INZY Inozyme Pharma	12.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	239.26 million	227.77 million	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable

INZY, AUPH, ARDX, and ELVN Headlines

Recent News About These Companies

Brokerages Set Inozyme Pharma, Inc. (NASDAQ:INZY) Target Price at $11.75

July 7, 2025 | americanbankingnews.com

Inozyme Pharma (NASDAQ:INZY) Stock Rating Upgraded by Wall Street Zen

July 5, 2025 | marketbeat.com

Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Hold" by Analysts

July 4, 2025 | marketbeat.com

Inozyme Pharma Inc News (INZY) - Investing.com

July 2, 2025 | investing.com

BioMarin Announces Completion of Acquisition of Inozyme

July 1, 2025 | prnewswire.com

Inozyme Pharma Inc Ordinary Shares

June 21, 2025 | morningstar.comM

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

June 20, 2025 | globenewswire.com

Inozyme Pharma Reports Increased Loss Amid Strategic Focus

June 9, 2025 | tipranks.com

BMRN to Acquire Inozyme Pharma

May 22, 2025 | finance.yahoo.com

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

May 21, 2025 | businesswire.com

StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A

May 18, 2025 | genengnews.comG

Jefferies Downgrades Inozyme Pharma (INZY)

May 17, 2025 | msn.com

Needham Downgrades Inozyme Pharma (INZY)

May 17, 2025 | msn.com

Leerink bullish on BioMarin following Inozyme deal, expects additional BD

May 17, 2025 | finance.yahoo.com

BioMarin to buy rare disease drugmaker Inozyme for $270M

May 16, 2025 | biopharmadive.comB

Inozyme Shares More Than Double in Surge Toward BioMarin's Buyout Price

May 16, 2025 | marketwatch.com

BioMarin to Acquire Inozyme Pharma for $270M

May 16, 2025 | contractpharma.comC

BioMarin stock rises following Inozyme Pharma acquisition

May 16, 2025 | in.investing.com

BioMarin buys Inozyme for $270 million

May 16, 2025 | thepharmaletter.comT

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens

May 16, 2025 | msn.com

BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal

May 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INZY, AUPH, ARDX, and ELVN Company Descriptions

Ardelyx NASDAQ:ARDX

$4.60 +0.10 (+2.11%)

As of 12:33 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Aurinia Pharmaceuticals NASDAQ:AUPH

$9.10 +0.11 (+1.17%)

As of 12:33 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Enliven Therapeutics NASDAQ:ELVN

$22.00 +0.35 (+1.59%)

As of 12:33 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)

As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time